טוען...
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunothe...
שמור ב:
| הוצא לאור ב: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499002/ https://ncbi.nlm.nih.gov/pubmed/28679395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0506-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|